1227 / 1851
RTOG 0522: C-RT
±
cetuximab for stage III-IV HNSCC
•
940 pts with stage III-IV HNSCC of the larynx and pharynx
• No significant differences in PFS or OS
• Triplet patients had higher rates of grade 3-4 mucositis
and skin reactions
Ang, JCO 2014